Ultragenyx Pharmaceutical Inc.
RARE
$21.34
-$0.37-1.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 673.00M | 630.37M | 609.93M | 590.46M | 560.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 673.00M | 630.37M | 609.93M | 590.46M | 560.00M |
| Cost of Revenue | 859.00M | 831.44M | 778.37M | 773.41M | 775.00M |
| Gross Profit | -186.00M | -201.07M | -168.44M | -182.96M | -215.00M |
| SG&A Expenses | 349.00M | 342.95M | 336.68M | 330.64M | 321.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.21B | 1.17B | 1.12B | 1.10B | 1.10B |
| Operating Income | -535.00M | -544.02M | -505.12M | -513.59M | -536.00M |
| Income Before Tax | -571.00M | -576.13M | -529.81M | -546.54M | -567.00M |
| Income Tax Expenses | 4.00M | 3.51M | 2.94M | 2.86M | 2.00M |
| Earnings from Continuing Operations | -575.00 | -579.65 | -532.75 | -549.40 | -569.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -575.00M | -579.65M | -532.75M | -549.40M | -569.00M |
| EBIT | -535.00M | -544.02M | -505.12M | -513.59M | -536.00M |
| EBITDA | -500.00M | -508.27M | -469.22M | -477.45M | -500.00M |
| EPS Basic | -5.83 | -5.94 | -5.53 | -5.88 | -6.34 |
| Normalized Basic EPS | -3.62 | -3.69 | -3.44 | -3.63 | -3.95 |
| EPS Diluted | -5.83 | -5.94 | -5.53 | -5.88 | -6.34 |
| Normalized Diluted EPS | -3.62 | -3.69 | -3.44 | -3.63 | -3.95 |
| Average Basic Shares Outstanding | 394.42M | 390.20M | 385.92M | 374.04M | 362.04M |
| Average Diluted Shares Outstanding | 394.42M | 390.20M | 385.92M | 374.04M | 362.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |